Prognostic Value of Cell-Cycle Regulation Biomarkers in Bladder Cancer

被引:50
作者
Mitra, Anirban P. [2 ,3 ]
Hansel, Donna E. [4 ,5 ,6 ]
Cote, Richard J. [1 ]
机构
[1] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA
[2] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA
[3] Univ So Calif, Keck Sch Med, Ctr Personalized Med, Los Angeles, CA 90033 USA
[4] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA
[5] Cleveland Clin, Dept Urol, Cleveland, OH 44106 USA
[6] Taussig Canc Inst, Cleveland, OH USA
关键词
GROWTH-FACTOR RECEPTOR; DEPENDENT KINASE INHIBITOR; UROTHELIAL CARCINOMA; RADICAL CYSTECTOMY; GENE-MUTATIONS; P53; IMMUNOHISTOCHEMISTRY; NUCLEAR OVEREXPRESSION; CLINICAL-SIGNIFICANCE; COMPLEMENTS CYTOLOGY; TRANSCRIPTION FACTOR;
D O I
10.1053/j.seminoncol.2012.08.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The determination of prognosis in bladder cancer is currently based on staging methods that rely primarily on the pathological stage of a tumor with limited objective correlates. The development and progression of bladder cancer involve alterations in several cellular pathways. Dysregulation in markers associated with cell-cycle regulation has been the most extensively examined molecular aberration in this cancer. Individual alterations of these markers have been associated with disease outcome, with several observations suggesting that their prognostic potential is independent of pathological stage. While many individual molecules in the cell growth receptor signaling, p53, and retinoblastoma (Rb) pathways have been identified, there is a general lack of consensus on which markers can be adopted in the clinical setting. More recent studies have suggested that the combination of markers as concise panels may be more beneficial in determining the degree of aggressiveness of a given tumor and its impending outcome than individual markers alone. This review will discuss alterations in molecules within pathways controlling cell-cycle regulation in the context of bladder cancer, and their impact on patient outcome when examined individually and in combination. Semin Oncol 39:524-533 (c) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:524 / 533
页数:10
相关论文
共 115 条
  • [1] Gene expression profiling of noninvasive primary urothelial tumours using microarrays
    Aaboe, M
    Marcussen, N
    Jensen, KME
    Thykjaer, T
    Dyrskjot, L
    Orntoft, TF
    [J]. BRITISH JOURNAL OF CANCER, 2005, 93 (10) : 1182 - 1190
  • [2] Neoadjuvant chemotherapy for invasive bladder cancer -: art. no. CD005246
    Abol-Enein, H
    Bassi, P
    Boyer, M
    Coppin, CML
    Cortesi, E
    Grossman, HB
    Hall, RR
    Horwich, A
    Malmström, PU
    Martinez-Piñeiro, JA
    Sengelov, L
    Sherif, A
    Wallace, DMA
    Bono, AV
    Goebell, PJ
    Groshen, S
    Stöckle, FMTM
    Studer, U
    Clarke, NW
    Raghavan, D
    Roberts, JT
    Sylvester, R
    Parmar, MKB
    Stewart, LA
    Tierney, JF
    Vale, CL
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (02):
  • [3] Abol-Enein H, 2003, LANCET, V361, P1927
  • [4] Allard P, 1998, BRIT J UROL, V81, P692
  • [5] NON-INVASIVE PAPILLARY CARCINOMA OF BLADDER ASSOCIATED WITH CARCINOMA INSITU
    ALTHAUSEN, AF
    PROUT, GR
    DALY, JJ
    [J]. JOURNAL OF UROLOGY, 1976, 116 (05) : 575 - 580
  • [6] [Anonymous], CA CANC J CLIN, DOI DOI 10.3322/CAAC.20107
  • [7] Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer
    Asakura, T
    Takano, Y
    Iki, M
    Suwa, Y
    Noguchi, S
    Kubota, Y
    Masuda, M
    [J]. JOURNAL OF UROLOGY, 1997, 158 (02) : 385 - 388
  • [8] Bakkar AA, 2003, CANCER RES, V63, P8108
  • [9] p14ARF links the tumour suppressors RB and p53
    Bates, S
    Phillips, AC
    Clark, PA
    Stott, F
    Peters, G
    Ludwig, RL
    Vousden, KH
    [J]. NATURE, 1998, 395 (6698) : 124 - 125
  • [10] Berggren P, 2003, CLIN CANCER RES, V9, P235